Dyslipidemias — particularly elevated low-density lipoprotein cholesterol (LDL-C) and related atherogenic lipoproteins — represent one of the most important modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD). The causal relationship between LDL-C and ASCVD is among the most rigorously established associations in medicine, supported by convergent evidence from epidemiology, Mendelian randomization studies, randomized controlled trials, and genetic disorders of lipoprotein metabolism.1 This module establishes the metabolic and clinical foundation for understanding lipid-lowering pharmacotherapy: how lipoproteins are structured and metabolized, what each lipid fraction contributes to cardiovascular risk, and how risk is formally quantified to guide treatment decisions. A firm grasp of these principles is prerequisite to rational prescribing of statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and other agents covered in subsequent modules.
Lipids are hydrophobic molecules that cannot circulate freely in plasma. They are transported as lipoproteins — macromolecular complexes consisting of a hydrophobic core of triglycerides (TG) and cholesterol esters surrounded by a phospholipid monolayer, free cholesterol, and one or more apolipoproteins.2 The apolipoprotein component governs receptor binding, enzyme activation, and metabolic fate. Lipoproteins are classified by density, which inversely correlates with lipid content. The major classes relevant to cardiovascular pharmacology are described below.
Chylomicrons are the largest, least dense particles, assembled in intestinal enterocytes to transport dietary (exogenous) triglycerides and cholesterol. They carry apolipoprotein B-48 (apoB-48) as their structural apolipoprotein. Chylomicrons are not directly atherogenic due to their large size, but their remnants — generated after lipoprotein lipase (LPL)-mediated TG hydrolysis — are small enough to penetrate the arterial intima and contribute to atherogenesis.2
Very low-density lipoproteins (VLDL) are assembled in the liver and serve as the primary vehicle for endogenous triglyceride export to peripheral tissues. VLDL carries apolipoprotein B-100 (apoB-100), apolipoprotein C-II (apoC-II, a LPL activator), and apolipoprotein E (apoE, a hepatic receptor ligand). As VLDL undergoes LPL-mediated TG hydrolysis in peripheral capillaries, it progressively shrinks and remodels through intermediate-density lipoprotein (IDL) to become LDL.3
Low-density lipoprotein (LDL) is the primary cholesterol-carrying particle in plasma and the dominant atherogenic lipoprotein. LDL is cholesterol-enriched and carries apoB-100 as its sole apolipoprotein. Apolipoprotein B-100 is the ligand recognized by the LDL receptor (LDLR) on hepatocytes, which mediates LDL clearance from the circulation. Reduced LDLR activity — whether due to genetic mutation (familial hypercholesterolemia), downregulation by dietary saturated fat, or PCSK9-mediated receptor degradation — results in elevated circulating LDL-C.1ยท3
Lipoprotein(a) [Lp(a)] is a distinct LDL-like particle in which apoB-100 is covalently linked to apolipoprotein(a) [apo(a)], a plasminogen-like glycoprotein. Lp(a) levels are greater than 90% genetically determined, making them largely refractory to lifestyle modification. Elevated Lp(a) (generally defined as >50 mg/dL or >125 nmol/L) confers independent ASCVD risk through both pro-atherogenic and pro-thrombotic mechanisms.4 It is an emerging pharmacological target.
High-density lipoprotein (HDL) is the smallest and densest lipoprotein, primarily carrying apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II). HDL mediates reverse cholesterol transport (RCT) — the efflux of cholesterol from peripheral tissues back to the liver for excretion — and exerts pleiotropic anti-atherogenic effects including anti-inflammatory, antioxidant, and antiplatelet activities.6 However, the relationship between HDL and cardiovascular outcomes is more complex than the simple "high-density lipoprotein cholesterol (HDL-C) is protective" paradigm: multiple trials of HDL-raising therapies have failed to reduce ASCVD events, suggesting that HDL function, not merely HDL particle concentration, is the biologically relevant variable.6
Understanding the three major lipoprotein metabolic pathways clarifies the mechanisms of action of lipid-lowering drugs and the rationale for combination therapy.
Dietary fat and cholesterol absorbed in the small intestine are packaged into chylomicrons by enterocytes. Chylomicrons enter the lymphatic system via lacteals and reach the systemic circulation via the thoracic duct. In peripheral tissues — particularly adipose tissue and skeletal muscle — apoC-II on the chylomicron surface activates endothelial LPL, which hydrolyzes core triglycerides, releasing free fatty acids for local utilization or storage.2 The triglyceride-depleted chylomicron remnants, now enriched in cholesterol and apoE, are rapidly cleared from the circulation by the liver via LDL receptor-related protein-1 (LRP1) and LDLR, using apoE as the ligand. Disorders of chylomicron metabolism — including LPL deficiency — cause severe hypertriglyceridemia and are not meaningfully responsive to statins; they require dietary fat restriction and specific therapies such as volanesorsen (an apoC-III antisense oligonucleotide).
The liver continuously synthesizes VLDL, driven primarily by the availability of fatty acid substrate (from de novo lipogenesis and free fatty acid uptake) and by apoB-100 synthesis. VLDL secretion is the dominant determinant of plasma triglyceride levels. Once secreted, VLDL undergoes the same LPL-mediated TG hydrolysis that remodels chylomicrons, progressing through IDL to LDL. The rate of LDL production and the rate of LDL clearance together determine steady-state LDL-C concentration.3 Hepatic LDL clearance is mediated by LDLR, which is dynamically regulated: intracellular cholesterol depletion upregulates LDLR expression (the mechanism exploited by statins), while PCSK9 — a serine protease secreted by the liver — binds LDLR on the hepatocyte surface and directs it to lysosomal degradation, reducing receptor recycling and thereby increasing plasma LDL-C.7 PCSK9 inhibition is now one of the most potent pharmacological strategies for LDL-C lowering.
Reverse cholesterol transport (RCT) is the process by which peripheral tissue cholesterol is retrieved and returned to the liver for biliary excretion. Nascent, lipid-poor HDL particles (pre-β HDL) acquire free cholesterol from macrophages and other peripheral cells via the ATP-binding cassette transporter A1 (ABCA1). The cholesterol is esterified by lecithin:cholesterol acyltransferase (LCAT), converting nascent HDL to mature spherical HDL.6 Cholesterol esters can be transferred from HDL to apoB-containing lipoproteins (VLDL, LDL) via cholesteryl ester transfer protein (CETP) — a process that lowers HDL-C and raises LDL-C — or delivered directly to the liver via scavenger receptor class B type I (SR-BI). CETP inhibitors (e.g., anacetrapib, evacetrapib) raised HDL-C dramatically in trials but failed to produce consistent ASCVD event reduction at clinically meaningful magnitudes, reinforcing the concept that HDL-C as a biomarker is an imperfect surrogate for HDL function.6
LDL-C remains the primary therapeutic target for ASCVD risk reduction. The causal evidence is overwhelming: each 1 mmol/L (approximately 38.7 mg/dL) reduction in LDL-C is associated with approximately a 22% reduction in major vascular events, with greater absolute benefit in higher-risk individuals.1 This relationship is consistent across statins, ezetimibe, and PCSK9 inhibitors — confirming that LDL-C lowering itself, not a drug-class-specific mechanism, drives event reduction. Mendelian randomization studies using LDL-C-lowering genetic variants (LDLR, PCSK9, Niemann-Pick C1-Like 1 protein (NPC1L1)) produce risk reductions concordant with the statin trial data, providing strong causal inference.1
Non-HDL cholesterol is calculated as total cholesterol minus HDL cholesterol and represents the cholesterol carried in all apoB-containing atherogenic particles: VLDL, IDL, LDL, and Lp(a). It is a more comprehensive atherogenic burden estimate than LDL-C alone, particularly in patients with hypertriglyceridemia or metabolic syndrome, where LDL-C may be underestimated by standard Friedewald calculation. Non-HDL-C is a secondary treatment target in the 2019 ACC/AHA guidelines.8 The treatment goal for non-HDL-C is typically 30 mg/dL higher than the corresponding LDL-C goal.
Apolipoprotein B-100 is present in exactly one copy per atherogenic lipoprotein particle (VLDL, IDL, LDL, Lp(a)). A direct plasma apoB measurement therefore reflects the total number of circulating atherogenic particles regardless of their cholesterol content, making it arguably a more accurate measure of atherogenic particle burden than LDL-C — particularly in patients with hypertriglyceridemia or small, dense LDL phenotype. Some guidelines (ESC 2019, Canadian Cardiovascular Society) formally incorporate apoB as a co-primary or preferred target, with a goal of <65–80 mg/dL depending on risk tier.9 ApoB measurement is increasingly available in clinical practice and is a more direct indicator of residual risk than LDL-C in treated patients.
Fasting triglycerides reflect the combined contribution of VLDL and remnant particles. Hypertriglyceridemia (TG ≥150 mg/dL) is associated with increased ASCVD risk, partly through its association with other metabolic abnormalities (insulin resistance, low HDL-C, small dense LDL) and partly through independent atherogenic effects of TG-rich remnant particles.2 Mendelian randomization studies using variants in LPL and apolipoprotein C-III gene (APOC3) support a causal role for TG-rich lipoproteins in ASCVD. Severe hypertriglyceridemia (TG ≥500–1000 mg/dL) carries acute pancreatitis risk. Pharmacological TG reduction is addressed in LD-05; the key point here is that ASCVD risk reduction through TG lowering requires reduction of apoB-containing remnant particles, not TG concentration per se.
Low HDL-C (<40 mg/dL in men, <50 mg/dL in women) is a negative risk factor and part of the metabolic syndrome definition. As discussed above, HDL-C as a plasma concentration has proven to be a poor pharmacological target; no agent that specifically raises HDL-C has demonstrated ASCVD event reduction in appropriately powered trials.6 HDL-C nonetheless retains clinical utility as a risk marker and a component of risk calculators. It should not be a primary pharmacological target.
Elevated Lp(a) is an independent, genetically mediated ASCVD risk factor that is not significantly modified by standard lipid-lowering therapy. Statins may modestly increase Lp(a) levels. PCSK9 inhibitors reduce Lp(a) by approximately 20–25%.4 Novel antisense oligonucleotides targeting apo(a) mRNA (pelacarsen) and small interfering RNA targeting hepatic apo(a) synthesis (olpasiran, zerlasiran) are in late-phase trials and represent a forthcoming class of targeted Lp(a)-lowering agents. Measurement of Lp(a) at least once in adults is recommended by ACC/AHA guidelines to refine risk assessment, particularly in patients with premature ASCVD, recurrent events on statin therapy, or a family history of premature CVD.8
The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease and the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol jointly define the current standard of care for lipid management in North America.8 The framework stratifies patients into benefit groups for whom statin therapy has demonstrated net clinical benefit.
Group 1 — Clinical ASCVD (secondary prevention): Patients with established ASCVD (prior MI, ACS, stable angina with coronary disease, coronary revascularization, stroke/TIA of atherosclerotic origin, or symptomatic peripheral arterial disease) are the highest-priority treatment group. High-intensity statin therapy is recommended for all patients aged ≤75 years; for very high-risk patients (multiple major ASCVD events or one major event plus multiple high-risk conditions), an LDL-C goal of <70 mg/dL is recommended, with addition of ezetimibe or a PCSK9 inhibitor if not achieved on maximally tolerated statin.8
Group 2 — Severe hypercholesterolemia (LDL-C ≥190 mg/dL): These patients have a lifetime burden of elevated LDL-C disproportionate to other risk factor accumulation and warrant high-intensity statin therapy without requiring formal 10-year risk calculation. This category captures most cases of heterozygous familial hypercholesterolemia (HeFH), though FH may be present even at lower LDL-C levels.
Group 3 — Diabetes mellitus, age 40–75, LDL-C 70–189 mg/dL: Moderate-intensity statin is recommended for all patients in this group; high-intensity statin is appropriate for those with 10-year ASCVD risk ≥10% or the presence of additional risk-enhancing features.
Group 4 — Primary prevention, age 40–75, LDL-C 70–189 mg/dL, no diabetes: Statin therapy is recommended when 10-year ASCVD risk is ≥7.5%, using the Pooled Cohort Equations (PCE). Risk discussion and shared decision-making are recommended for patients in the intermediate-risk range (7.5–20%).
The PCE estimate the 10-year risk of a first atherosclerotic cardiovascular event (fatal or non-fatal MI, or fatal or non-fatal stroke) in patients aged 40–79 without prior ASCVD or diabetes, using age, sex, race, total cholesterol, HDL-C, systolic blood pressure, antihypertensive use, smoking status, and diabetes status.8 Risk categories: low (<5%), borderline (5–<7.5%), intermediate (7.5–<20%), and high (≥20%). The PCE are known to overestimate risk in some contemporary cohorts; the American College of Cardiology (ACC) ASCVD Risk Estimator Plus incorporates lifetime risk and risk-enhancing factors as complementary inputs.
For patients in the borderline-to-intermediate risk range in whom statin initiation is uncertain, the 2019 ACC/AHA guidelines recommend consideration of risk-enhancing factors that favor statin therapy:8 family history of premature ASCVD (first-degree relative, male <55 years, female <65 years); LDL-C persistently ≥160 mg/dL; metabolic syndrome; chronic kidney disease; chronic inflammatory conditions (RA, psoriasis, HIV); history of premature menopause or pre-eclampsia; South Asian ancestry; elevated triglycerides (≥175 mg/dL); elevated apoB (≥130 mg/dL); elevated Lp(a) (≥50 mg/dL); elevated high-sensitivity CRP (≥2.0 mg/L); and ankle-brachial index <0.9. When risk decision remains uncertain after considering these factors, coronary artery calcium (CAC) scoring is recommended as a selective tie-breaker.8 A CAC score of 0 in an intermediate-risk patient supports deferring statin therapy (with reassessment in 5–10 years); a CAC score ≥100 AU or ≥75th percentile for age/sex/race strongly favors statin initiation. CAC scoring is not recommended for patients already established to be high-risk.
The ACC/AHA 2018 guideline takes a statin-intensity–based approach: the primary recommendation is to use the appropriate statin intensity (high, moderate, or low) based on risk group, with percentage LDL-C reduction as the key metric. Specific LDL-C numerical targets are reserved for very high-risk secondary prevention (<70 mg/dL, with add-on therapy if not met) and primary prevention with LDL-C ≥190 mg/dL (≥50% reduction goal).8 In contrast, the 2019 ESC/European Atherosclerosis Society (EAS) guidelines adopt a more aggressive treat-to-target approach: for very high-risk patients (established ASCVD or equivalent), the LDL-C goal is <55 mg/dL and ≥50% reduction from baseline; for high-risk patients, <70 mg/dL and ≥50% reduction; for moderate risk, <100 mg/dL; and for low risk, <116 mg/dL.9 The ESC guidelines also endorse apoB and non-HDL-C as co-primary targets. Clinicians practicing in international or academic settings should be familiar with both frameworks, as the ESC targets are increasingly influential worldwide.
Even patients achieving LDL-C goals on high-intensity statin therapy retain substantial residual ASCVD risk. This residual risk is attributable to multiple mechanisms: inflammation (elevated high-sensitivity CRP); elevated TG-rich remnant particles (non-HDL-C above target); elevated Lp(a); hypertension; diabetes; and plaque burden established before therapy initiation.10 The recognition of residual risk has driven the development of add-on therapies including ezetimibe (IMPROVE-IT), PCSK9 inhibitors (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER), ODYSSEY OUTCOMES trial (ODYSSEY OUTCOMES)), icosapentaenoic acid (REDUCE-IT), and anti-inflammatory agents (colchicine — Colchicine Cardiovascular Outcomes Trial (COLCOT), LoDoCo2). This concept is central to understanding why combination lipid-lowering therapy is increasingly standard of care in high-risk patients, and it frames the pharmacological content of LD-02 through LD-06.
Dyslipidemias are broadly classified as primary (genetic or polygenic in origin) or secondary (arising from an underlying medical condition or drug effect). This distinction matters clinically because secondary causes must be identified and addressed before or alongside lipid-lowering pharmacotherapy — treating the lipid abnormality without correcting the underlying cause produces suboptimal results and may delay diagnosis of a treatable condition.
Primary dyslipidemias of greatest pharmacological relevance include familial hypercholesterolemia, which is caused by loss-of-function mutations in the low-density lipoprotein receptor gene and results in markedly elevated low-density lipoprotein cholesterol from birth; familial combined hyperlipidemia, which is a polygenic disorder characterized by variable elevations in both low-density lipoprotein cholesterol and triglycerides, often with low high-density lipoprotein cholesterol; familial hypertriglyceridemia, which involves elevated hepatic very low-density lipoprotein production with triglycerides typically in the range of 200 to 500 milligrams per deciliter; and familial chylomicronemia syndrome, caused by lipoprotein lipase deficiency or related genetic defects, producing severe hypertriglyceridemia above 1,000 milligrams per deciliter with pancreatitis risk.
Secondary causes of dyslipidemia are numerous and clinically important to exclude before initiating or escalating pharmacotherapy. Hypothyroidism causes elevated low-density lipoprotein cholesterol through reduced low-density lipoprotein receptor expression; thyroid-stimulating hormone should be checked in any patient presenting with unexplained hypercholesterolemia. Uncontrolled type 2 diabetes and insulin resistance produce the characteristic diabetic dyslipidemia triad: elevated triglycerides, low high-density lipoprotein cholesterol, and a predominance of small dense low-density lipoprotein particles despite often-normal calculated low-density lipoprotein cholesterol. Nephrotic syndrome causes severe hypercholesterolemia through increased hepatic lipoprotein synthesis driven by reduced oncotic pressure. Chronic kidney disease impairs lipoprotein clearance and produces mixed dyslipidemia. Obstructive liver disease reduces hepatic low-density lipoprotein receptor activity. Medications are a frequently overlooked secondary cause: thiazide diuretics and beta-blockers can raise triglycerides and reduce high-density lipoprotein cholesterol; glucocorticoids raise low-density lipoprotein cholesterol and triglycerides; atypical antipsychotics produce mixed dyslipidemia; and protease inhibitors used in human immunodeficiency virus treatment cause severe hypertriglyceridemia.
The clinical phenotype of mixed dyslipidemia — elevated triglycerides combined with low high-density lipoprotein cholesterol, often with normal or only modestly elevated low-density lipoprotein cholesterol — deserves particular attention because it is frequently undertreated. This phenotype, which characterizes the metabolic syndrome and type 2 diabetes, carries substantial residual atherosclerotic cardiovascular disease risk even when low-density lipoprotein cholesterol is at goal on statin therapy. The residual risk in this phenotype is driven by elevated apolipoprotein B-containing remnant particles and reduced high-density lipoprotein cholesterol-mediated reverse cholesterol transport, and it is the primary rationale for considering add-on non-statin therapies in selected patients.
The 2018 American College of Cardiology/American Heart Association guideline uses a risk-stratified, statin-intensity approach. The primary metric is percentage low-density lipoprotein cholesterol reduction, with numerical targets reserved for the highest-risk groups. For clinical purposes, the following framework integrates both the American College of Cardiology/American Heart Association and the European Society of Cardiology/European Atherosclerosis Society targets.
For patients with established atherosclerotic cardiovascular disease — the very high-risk secondary prevention group — the American College of Cardiology/American Heart Association guideline recommends high-intensity statin therapy as baseline with a low-density lipoprotein cholesterol goal below 70 milligrams per deciliter. The European Society of Cardiology/European Atherosclerosis Society guideline is more aggressive, targeting low-density lipoprotein cholesterol below 55 milligrams per deciliter and at least 50 percent reduction from untreated baseline. Patients with multiple prior atherosclerotic cardiovascular disease events or established disease plus additional high-risk conditions are classified as extreme risk by the European Society of Cardiology, with a low-density lipoprotein cholesterol target below 40 milligrams per deciliter. In practice, the European Society of Cardiology targets have become increasingly influential globally and are the framework used by many academic centers worldwide.
For patients with familial hypercholesterolemia without established atherosclerotic cardiovascular disease — high-risk primary prevention — the American College of Cardiology/American Heart Association recommends a low-density lipoprotein cholesterol goal below 100 milligrams per deciliter, while the European Society of Cardiology targets below 70 milligrams per deciliter in this group. For patients with diabetes between the ages of 40 and 75 with low-density lipoprotein cholesterol between 70 and 189 milligrams per deciliter, moderate-intensity statin is the minimum; high-intensity statin is appropriate when 10-year atherosclerotic cardiovascular disease risk is 10 percent or greater. For primary prevention patients with a 10-year atherosclerotic cardiovascular disease risk of 7.5 percent or greater using the Pooled Cohort Equations, moderate- to high-intensity statin is recommended based on shared decision-making.
Non-high-density lipoprotein cholesterol and apolipoprotein B serve as secondary targets, particularly in patients with hypertriglyceridemia or metabolic syndrome where low-density lipoprotein cholesterol may underestimate atherogenic burden. The non-high-density lipoprotein cholesterol goal is 30 milligrams per deciliter higher than the corresponding low-density lipoprotein cholesterol goal at each risk tier. An apolipoprotein B goal below 65 milligrams per deciliter corresponds to the extreme-risk low-density lipoprotein cholesterol target; below 80 milligrams per deciliter corresponds to the very-high-risk target; and below 100 milligrams per deciliter corresponds to high-risk targets.
When statin therapy alone is insufficient to achieve low-density lipoprotein cholesterol targets — whether because of patient intolerance at high intensity, genetically mediated resistance such as familial hypercholesterolemia, or a very low treatment target in extreme-risk patients — the mechanistic complementarity of available non-statin agents provides a rational framework for sequential combination therapy.
Statins reduce intracellular hepatic cholesterol synthesis by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase. The resulting intracellular cholesterol depletion upregulates low-density lipoprotein receptor expression, increasing clearance of low-density lipoprotein from the circulation. This also upregulates proprotein convertase subtilisin/kexin type 9 expression — the so-called proprotein convertase subtilisin/kexin type 9 co-induction effect — which partially limits the low-density lipoprotein receptor upregulation by directing receptors toward lysosomal degradation.
Ezetimibe reduces intestinal cholesterol absorption via Niemann-Pick C1-Like 1 protein inhibition, decreasing cholesterol delivery to the liver. This triggers a further compensatory increase in hepatic low-density lipoprotein receptor expression through the sterol regulatory element-binding protein pathway, producing additive low-density lipoprotein cholesterol lowering that is mechanistically distinct from statin action. The combination of statin plus ezetimibe reduces low-density lipoprotein cholesterol by approximately 60 to 65 percent from untreated baseline.
Proprotein convertase subtilisin/kexin type 9 inhibitors — the monoclonal antibodies evolocumab and alirocumab, and the small interfering ribonucleic acid agent inclisiran — prevent proprotein convertase subtilisin/kexin type 9-mediated degradation of low-density lipoprotein receptors on hepatocyte surfaces, dramatically amplifying the number of receptors available for low-density lipoprotein clearance. Their effect is additive to both statins and ezetimibe because they address the proprotein convertase subtilisin/kexin type 9-mediated counter-regulatory mechanism that partially offsets statin-induced receptor upregulation. Triple therapy with high-intensity statin plus ezetimibe plus a proprotein convertase subtilisin/kexin type 9 inhibitor can reduce low-density lipoprotein cholesterol by 70 to 85 percent from untreated baseline, achieving levels of 20 to 30 milligrams per deciliter in most patients — levels considered safe based on the cardiovascular outcomes data from Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk and ODYSSEY OUTCOMES.
The practical sequencing of combination therapy follows the guideline-endorsed stepwise approach: first, optimize statin intensity; second, add ezetimibe if the low-density lipoprotein cholesterol target is not achieved on maximally tolerated statin; third, add a proprotein convertase subtilisin/kexin type 9 inhibitor if the target remains unmet on statin plus ezetimibe. This sequence reflects cost-effectiveness considerations — ezetimibe is inexpensive and generic, while proprotein convertase subtilisin/kexin type 9 inhibitors remain costly — as well as the incremental nature of the evidence base. In certain high-risk scenarios such as very high baseline low-density lipoprotein cholesterol or recurrent atherosclerotic cardiovascular disease events, earlier initiation of proprotein convertase subtilisin/kexin type 9 inhibitors is appropriate without waiting to fail ezetimibe first.
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472
doi:10.1093/eurheartj/ehx144Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies. Eur Heart J. 2021;42(47):4791–4806
doi:10.1093/eurheartj/ehab551Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009;29(4):431–438
doi:10.1161/ATVBAHA.108.179564Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692–711
doi:10.1016/j.jacc.2016.11.042Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15(2):104–116
doi:10.1038/nri3793Rye KA, Barter PJ. Cardioprotective functions of HDLs. J Lipid Res. 2014;55(2):168–179
doi:10.1194/jlr.R039297Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114(6):1022–1036
doi:10.1161/CIRCRESAHA.114.301621Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285–e350
doi:10.1016/j.jacc.2018.11.003Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111–188
doi:10.1093/eurheartj/ehz455Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302–1309
doi:10.1001/jama.2012.366